What is Endoret® (prgf®)?

Endoret® (prgf®) is an advanced system for obtaining platelet-rich autologous plasma.

It is based on the formulation and use of the patient's own proteins with biological activity, growth factors and fibrin biomaterial for the stimulation and acceleration of tissue healing and regeneration.

It is 100% biocompatible technology, with excellent versatility, safety and effectiveness. The potential of this technology derives from the global effect of the platelets' growth factors which include, among others, VEGF, FGF, PDGF, TGF-B, EGF, IGF-I. These factors influence a series of biological processes that favour cellular migration, growth and morphogenesis. In addition they accelerate the “on site” formation process of a biodegradable fibrin matrix that acts as a temporary “scaffold” that facilitates tissue regeneration. The versatility, safety and effectiveness of this system opens the door to personalised medicine, which is already being applied in many medical and scientific fields, including oral and maxillofacial surgery, oral implantology, orthopaedics, ulcer treatments, sports medicine, facial resurfacing, ophthalmology and tissue engineering, among others.

Application of Endoret® (prgf®) in Odontology

Endoret® (prgf®) Is an advanced system there is for obtaining platelet-rich autologous plasma, and can be applied directly on the dental implant surface improving osseointegration, and with it, the primary stability of the implant surgery.

PRGF un producto muy versatil

Endoret® (prgf®) formulations

The complete restoration of the insertion system of each defect treated is not yet a reality. To achieve the regeneration of the periodontium a series of biological events must unfold that include lithogenesis, chemotaxis, cellular adhesion and differentiation, which would lead to a functional periodontal unit.

Endoret® (prgf®) is used in oral surgery to promote bone and adjacent soft tissue regeneration in post-extraction defects. The method consists of filling and sealing the post-extraction defects with the standard biological matrix and with autologous fibrin.

The wetting of the implant surfaces with non-activated Endoret® (prgf®) creates a much more favourable biological environment for osseointegration, as a protein interface is achieved that favours cell migration over the new fibrin bridges created between the osseous wall and the implant surface.

Intended for international use only. Indications for use of products and/or therapies contained herein may not be cleared /approved for use by the following Health international agencies: US Food & Drug Administration, Health Canada or Japanese Health Ministry. To access the specific information of your market, use the country selector located on the top menu of this page.

Are you interested in contacting us?